España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teofarma s.r.l. - uroquinasa - polvo y disolvente para soluciÓn para perfusiÓn - 100.000 ui - uroquinasa 100000 ui - uroquinasa

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teofarma s.r.l. - uroquinasa - polvo y disolvente para soluciÓn para perfusiÓn - 250.000 ui - uroquinasa 250000 ui - uroquinasa

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ucb pharma, s.a. - uroquinasa - excipientes: manitol (e-421),hidrogenofosfato de sodio dodecahidrato,edetato de disodio,cloruro de sodio - agentes antitrombÓticos - enzimas - uroquinasa

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - inmunosupresores - la artritis reumatoide (ar)kineret está indicado en adultos para el tratamiento de los signos y síntomas de la ar en combinación con metotrexato, con una respuesta inadecuada a metotrexato solo. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret debe administrarse en combinación con colchicina, si es apropiado. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

major pharmaceuticals, livonia, estados unidos de américa. - subsalicilato de bismuto - tableta masticable - 262,0 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

major pharmaceuticals. - subsalicilato de bismuto (total de salicilato 102 mg) - tableta masticable - 262 mg

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

distribuidora drogueria sagitario s.r.l. - polvo liofilizado para solucion inyectable